On September 19, 2024, GC Therapeutics (GCTx), a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines, launched and announced the successful completion of a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC,将GCTX筹集的总资本提高到7500万美元。Wilson Sonsini Goodrich&Rosati就交易建议GC Therapeutics。Wilson Sonsini Goodrich&Rosati就交易建议GC Therapeutics。
Radar Therapeutics正在开发采用RNA传感器的晚期遗传和基于mRNA的治疗方法。这些传感器根据细胞中存在的其他RNA调节其表达,从而使药物有效载荷的精确递送到预期的细胞中。这种受控过程可通过防止治疗影响非目标细胞来最大程度地减少全身毒性副作用。通过其雷达平台,Radar Therapeutics旨在创建“智能”,科学设计的精确治疗。融资将支持Radar Therapeutics内部计划,团队扩展和合作的进步。